SwePub
Sök i LIBRIS databas

  Extended search

WFRF:(Jacobsen Paul B.)
 

Search: WFRF:(Jacobsen Paul B.) > (2020-2024) > Remission and low d...

  • Barber, Megan R.W.Cumming School of Medicine (author)

Remission and low disease activity are associated with lower healthcare costs : results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort

  • Article/chapterEnglish2024

Publisher, publication year, extent ...

  • 2024

Numbers

  • LIBRIS-ID:oai:lup.lub.lu.se:d903e1cb-1655-4f7b-a6c8-91fd6c2ad656
  • https://lup.lub.lu.se/record/d903e1cb-1655-4f7b-a6c8-91fd6c2ad656URI
  • https://doi.org/10.1136/ard-2024-225613DOI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:art swepub-publicationtype
  • Subject category:ref swepub-contenttype

Notes

  • Objectives: This study aims to determine the independent impact of definitions of remission/low disease activity (LDA) on direct/indirect costs (DCs, ICs) in a multicentre inception cohort. Methods: Patients from 31 centres in 10 countries were enrolled within 15 months of diagnosis and assessed annually. Five mutually exclusive disease activity states (DAS) were defined as (1) remission off-treatment: clinical (c) SLEDAI-2K=0, without prednisone/immunosuppressants; (2) remission on-treatment: cSLEDAI-2K=0, prednisone ≤5 mg/day and/or maintenance immunosuppressants; (3) LDA-Toronto Cohort (TC): cSLEDAI-2K≤2, without prednisone/immunosuppressants; (4) modified lupus LDA state (mLLDAS): SLEDAI-2K≤4, no activity in major organs/systems, no new activity, prednisone ≤7.5 mg/day and/or maintenance immunosuppressants and (5) active: all remaining assessments. At each assessment, patients were stratified into the most stringent DAS fulfilled and the proportion of time in a DAS since cohort entry was determined. Annual DCs/ICs (2021 Canadian dollars) were based on healthcare use and lost workforce/non-workforce productivity over the preceding year. The association between the proportion of time in a DAS and annual DC/IC was examined through multivariable random-effects linear regressions. Results: 1692 patients were followed a mean of 9.7 years; 49.0% of assessments were active. Remission/LDA (per 25% increase in time in a remission/LDA state vs active) were associated with lower annual DC/IC: remission off-treatment (DC -$C1372; IC -$C2507), remission on-treatment (DC -$C973; IC -$C2604,) LDA-TC (DC -$C1158) and mLLDAS (DC -$C1040). There were no cost differences between remission/LDA states. Conclusions: Our data suggest that systemic lupus erythematosus patients who achieve remission, both off and on-therapy, and reductions in disease activity incur lower costs than those experiencing persistent disease activity.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Ugarte-Gil, Manuel FranciscoHospital Nacional Guillermo Almenara Irigoyen, EsSalud,Scientific University of the South, Lima (author)
  • Hanly, John G.Dalhousie University (author)
  • Urowitz, Murray B.Toronto Western Hospital (author)
  • St-Pierre, YvanMcGill University Health Center (author)
  • Gordon, Caroline (author)
  • Bae, Sang CheolHanyang University Hospital for Rheumatic Disease (author)
  • Romero-Diaz, JuanitaSalvador Zubirán National Institute of Health Sciences and Nutrition (author)
  • Sanchez-Guerrero, JorgeMount Sinai Hospital of University of Toronto (author)
  • Bernatsky, SashaMcGill University Health Center (author)
  • Wallace, Daniel J.Cedars-Sinai Medical Center (author)
  • Isenberg, David A.University College London (author)
  • Rahman, AnisurUniversity College London (author)
  • Merrill, Joan T.Oklahoma Medical Research Foundation (author)
  • Fortin, Paul R.Laval University (author)
  • Gladman, Dafna D.University of Toronto (author)
  • Bruce, Ian N.University of Manchester,Manchester University NHS Foundation Trust (author)
  • Petri, Michelle A.Johns Hopkins University School of Medicine (author)
  • Ginzler, Ellen M. (author)
  • Dooley, Mary AnneUniversity of North Carolina (author)
  • Ramsey-Goldman, RosalindNorthwestern University Feinberg School of Medicine (author)
  • Manzi, SusanAllegheny Health Network (author)
  • Jönsen, AndreasLund University,Lunds universitet,Reumatologi och molekylär skelettbiologi,Sektion III,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Lund SLE Research Group,Forskargrupper vid Lunds universitet,Rheumatology,Section III,Department of Clinical Sciences, Lund,Faculty of Medicine,Lund University Research Groups(Swepub:lu)reum-ajo (author)
  • Van Vollenhoven, Ronald F.University of Amsterdam (author)
  • Aranow, CynthiaFeinstein Institute for Medical Research (author)
  • Mackay, MegganFeinstein Institute for Medical Research (author)
  • Ruiz-Irastorza, GuillermoHospital de Cruces (author)
  • Lim, S. SamEmory University (author)
  • Inanc, Murat (author)
  • Kalunian, Kenneth C.University of California, San Diego (author)
  • Jacobsen, SørenCopenhagen University Hospital (author)
  • Peschken, Christine A.University of Manitoba (author)
  • Kamen, Diane L.Medical University of South Carolina (author)
  • Askanase, AncaColumbia University (author)
  • Pons-Estel, Bernardo A.Grupo Oroño-Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR) (author)
  • Cardwell, Francesca S.University of Waterloo (author)
  • Alarcón, Graciela S. (author)
  • Clarke, Ann E.Cumming School of Medicine (author)
  • Cumming School of MedicineHospital Nacional Guillermo Almenara Irigoyen, EsSalud (creator_code:org_t)

Related titles

  • In:Annals of the Rheumatic Diseases0003-4967

Internet link

Find in a library

To the university's database

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view